Recent advancements in immune checkpoint inhibition have expanded beyond PD-1 and CTLA-4 inhibitors, with promising candidates targeting additional immune checkpoints to overcome the immunosuppressive microenvironment in GBM. The gene discussed is CTLA4; the disease is glioblastoma.